2026 ACHONDROPLASIA & SKELETAL DYSPLASIA RESEARCH CONFERENCE • ORLANDO, FL
SOURCE – Ascendis Pharma A/S • Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal…
SOURCE: Ascendis Pharma, GlobeNewswire TransCon CNP is the first investigational product to demonstrate improvements in health-related quality of life and disease impacts in children with achondroplasia COPENHAGEN, Denmark, Dec. 20,…
SOURCE: VISEN Pharmaceuticals (Nov 16th, 2023, Shanghai, China) – VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, is pleased to announce the topline results from the ACcomplisH…
